[
  {
    "ts": null,
    "headline": "Novo Nordisk's Downgraded Expectations - What The Market Is (Obviously) Missing",
    "summary": "Novo Nordisk A/S shares plunged after a Q2 revenue update and 2025 guidance downgrade. Click here to find out why NVO stock is a Buy.",
    "url": "https://finnhub.io/api/news?id=7e59d70622b5592218bcd72bff17a075183b9d3b0d00021bf9df3b03597e9f63",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753803000,
      "headline": "Novo Nordisk's Downgraded Expectations - What The Market Is (Obviously) Missing",
      "id": 136122654,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/829849422/image_829849422.jpg?io=getty-c-w1536",
      "related": "AMGN",
      "source": "SeekingAlpha",
      "summary": "Novo Nordisk A/S shares plunged after a Q2 revenue update and 2025 guidance downgrade. Click here to find out why NVO stock is a Buy.",
      "url": "https://finnhub.io/api/news?id=7e59d70622b5592218bcd72bff17a075183b9d3b0d00021bf9df3b03597e9f63"
    }
  },
  {
    "ts": null,
    "headline": "Bispecific Antibodies Market Report 2025- 2035, with Profiles of Akeso Biopharma, Alexion, Amgen, Genmab, Immunocore, Linton Pharm, Merck, OncXerna Therapeutics, Zymeworks, and More",
    "summary": "The global bispecific antibodies market, valued at USD 5.6 billion in 2025, is set to soar to USD 16.8 billion by 2035, growing at a CAGR of 9.5%. Key drivers include advancements in monoclonal antibodies and strategic partnerships. North America leads, with hematological malignancies emerging rapidly. Bispecific Antibodies Market Development Pipeline Bispecific Antibodies Market Development Pipeline Bispecific Antibodies Market Distribution Bispecific Antibodies Market Distribution Dublin, July",
    "url": "https://finnhub.io/api/news?id=95cf96abdce4c5fb35d78ebfc3e27c013a4aeff7ed1b71a043d4cd0daaff100f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753801380,
      "headline": "Bispecific Antibodies Market Report 2025- 2035, with Profiles of Akeso Biopharma, Alexion, Amgen, Genmab, Immunocore, Linton Pharm, Merck, OncXerna Therapeutics, Zymeworks, and More",
      "id": 136119261,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "The global bispecific antibodies market, valued at USD 5.6 billion in 2025, is set to soar to USD 16.8 billion by 2035, growing at a CAGR of 9.5%. Key drivers include advancements in monoclonal antibodies and strategic partnerships. North America leads, with hematological malignancies emerging rapidly. Bispecific Antibodies Market Development Pipeline Bispecific Antibodies Market Development Pipeline Bispecific Antibodies Market Distribution Bispecific Antibodies Market Distribution Dublin, July",
      "url": "https://finnhub.io/api/news?id=95cf96abdce4c5fb35d78ebfc3e27c013a4aeff7ed1b71a043d4cd0daaff100f"
    }
  },
  {
    "ts": null,
    "headline": "Amgen (AMGN) Reports Next Week: Wall Street Expects Earnings Growth",
    "summary": "Amgen (AMGN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.",
    "url": "https://finnhub.io/api/news?id=d3346501356edde0152e6cfeb77bbdd23c2240613351ef41878d6dd282739f64",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753797631,
      "headline": "Amgen (AMGN) Reports Next Week: Wall Street Expects Earnings Growth",
      "id": 136119335,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Amgen (AMGN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.",
      "url": "https://finnhub.io/api/news?id=d3346501356edde0152e6cfeb77bbdd23c2240613351ef41878d6dd282739f64"
    }
  },
  {
    "ts": null,
    "headline": "Amgen (AMGN) Just Flashed Golden Cross Signal: Do You Buy?",
    "summary": "Is it a good or bad thing when a stock experiences a golden cross technical event?",
    "url": "https://finnhub.io/api/news?id=578a38ef9107804ca33cfb1555ff9d141911cdcf72cd84a3838bb2dbf751d7c1",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753797301,
      "headline": "Amgen (AMGN) Just Flashed Golden Cross Signal: Do You Buy?",
      "id": 136119336,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Is it a good or bad thing when a stock experiences a golden cross technical event?",
      "url": "https://finnhub.io/api/news?id=578a38ef9107804ca33cfb1555ff9d141911cdcf72cd84a3838bb2dbf751d7c1"
    }
  },
  {
    "ts": null,
    "headline": "Are You a Value Investor? This 1 Stock Could Be the Perfect Pick",
    "summary": "Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.",
    "url": "https://finnhub.io/api/news?id=9d4811d4b05d95bdbb8f9aee40e042ac85a734a8edabfc6522c36da7c678babe",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753796401,
      "headline": "Are You a Value Investor? This 1 Stock Could Be the Perfect Pick",
      "id": 136119337,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.",
      "url": "https://finnhub.io/api/news?id=9d4811d4b05d95bdbb8f9aee40e042ac85a734a8edabfc6522c36da7c678babe"
    }
  },
  {
    "ts": null,
    "headline": "Aristotle Global Equity Q2 2025 Commentary",
    "summary": "Aristotle Global Equity Q2 2025 Commentary",
    "url": "https://finnhub.io/api/news?id=488cb0fa1cf0e5dfd0e9513267a6c0d58bf7a6728e2bb9b110bc2f38550fd7b8",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753777980,
      "headline": "Aristotle Global Equity Q2 2025 Commentary",
      "id": 136117308,
      "image": "",
      "related": "AMGN",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=488cb0fa1cf0e5dfd0e9513267a6c0d58bf7a6728e2bb9b110bc2f38550fd7b8"
    }
  },
  {
    "ts": null,
    "headline": "BME: The Resilient Income Investment Of The Healthcare Industry",
    "summary": "BlackRock Health Sciences Trust offers a resilient 8.63% dividend yield, low expense ratio, and conservative, low-risk positioning. See more on BME ETF here.",
    "url": "https://finnhub.io/api/news?id=78240d01203e7108640de3e61a12e015ad3c84d30c01e10965bf01bcf0b6bbe0",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753747321,
      "headline": "BME: The Resilient Income Investment Of The Healthcare Industry",
      "id": 136112843,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1635084121/image_1635084121.jpg?io=getty-c-w1536",
      "related": "AMGN",
      "source": "SeekingAlpha",
      "summary": "BlackRock Health Sciences Trust offers a resilient 8.63% dividend yield, low expense ratio, and conservative, low-risk positioning. See more on BME ETF here.",
      "url": "https://finnhub.io/api/news?id=78240d01203e7108640de3e61a12e015ad3c84d30c01e10965bf01bcf0b6bbe0"
    }
  }
]